Revvity Operating Income Over Time
| RVTY Stock | 101.10 3.65 3.48% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Revvity Performance and Revvity Correlation. Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revvity. Anticipated expansion of Revvity directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revvity assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.125 | Dividend Share 0.28 | Earnings Share 2.06 | Revenue Per Share | Quarterly Revenue Growth 0.059 |
The market value of Revvity is measured differently than its book value, which is the value of Revvity that is recorded on the company's balance sheet. Investors also form their own opinion of Revvity's value that differs from its market value or its book value, called intrinsic value, which is Revvity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revvity's market value can be influenced by many factors that don't directly affect Revvity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Revvity's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revvity should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Revvity's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Revvity and related stocks such as Qiagen NV, Ensign Group, and Guardant Health Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QGEN | 4.7 M | 99.6 M | 169.8 M | 63.3 M | 161.7 M | 179.5 M | 98.8 M | 153.4 M | 266.6 M | (26.1 M) | 386.4 M | 630.1 M | 531.5 M | 409.9 M | 97.7 M | 520.3 M | 546.3 M |
| ENSG | 5.9 M | 90.7 M | 78.3 M | 57.9 M | 72.9 M | 93.1 M | 91.8 M | 43.2 M | 84.9 M | 129.2 M | 223.2 M | 260.5 M | 296.8 M | 255.4 M | 358.3 M | 433.8 M | 455.5 M |
| GH | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (76.6 M) | (92.9 M) | (82.4 M) | (254.9 M) | (411 M) | (544.4 M) | (564.7 M) | (443.6 M) | (399.2 M) | (419.2 M) |
| RDY | 17.4 M | 18.3 B | 21.1 B | 26 B | 26.3 B | 29.6 B | 13.5 B | 11.9 B | 20.9 B | 16 B | 431.4 M | 29.5 B | 57.1 B | 67.7 B | 71.8 B | 82.6 B | 86.8 B |
| ICLR | 42.1 M | 39.3 M | 72.4 M | 121.2 M | 202.3 M | 281.5 M | 311.7 M | 338.3 M | 373.4 M | 433.4 M | 391.5 M | 378.5 M | 795.2 M | 956.2 M | 1.1 B | 1.3 B | 1.3 B |
| HIMS | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (75.8 M) | (74.4 M) | (15.1 M) | (115 M) | (68.7 M) | (29.5 M) | 61.9 M | 71.2 M | 74.7 M |
| EXAS | (4 M) | (28.8 M) | (52.6 M) | (46.8 M) | (100.5 M) | (159.1 M) | (169 M) | (118.3 M) | (159.5 M) | (233.8 M) | (767.7 M) | (855.7 M) | (593.5 M) | (215 M) | (1 B) | (943.8 M) | (896.6 M) |
| CRL | 35.3 M | 174.3 M | 165.8 M | 151.4 M | 177.7 M | 206.4 M | 237.6 M | 288.3 M | 331.4 M | 351.2 M | 432.7 M | 589.9 M | 651 M | 617.3 M | 227.3 M | 261.4 M | 214.9 M |
| SOLV | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.9 B | 1.7 B | 1.7 B | 1 B | 932.4 M | 1.2 B |
| ALGN | (14.7 M) | 90.4 M | 85.6 M | 94.2 M | 193.6 M | 188.6 M | 248.9 M | 353.6 M | 466.6 M | 542.5 M | 387.2 M | 976.4 M | 642.6 M | 643.3 M | 607.6 M | 545.8 M | 573 M |
Revvity and related stocks such as Qiagen NV, Ensign Group, and Guardant Health Operating Income description
Operating Income is the amount of profit realized from Revvity operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Revvity is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Revvity | RVTY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 77 4th Avenue, |
| Exchange | New York Stock Exchange |
null 101.1
Additional Tools for Revvity Stock Analysis
When running Revvity's price analysis, check to measure Revvity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revvity is operating at the current time. Most of Revvity's value examination focuses on studying past and present price action to predict the probability of Revvity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revvity's price. Additionally, you may evaluate how the addition of Revvity to your portfolios can decrease your overall portfolio volatility.